Epigenetic regulation as a new target for breast cancer therapy - PubMed (original) (raw)
Review
Epigenetic regulation as a new target for breast cancer therapy
Vered Stearns et al. Cancer Invest. 2007 Dec.
No abstract available
Similar articles
- Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulié A, Toubert ME, Delva L, Chomienne C. Cras A, et al. Oncogene. 2007 Jun 7;26(27):4018-24. doi: 10.1038/sj.onc.1210178. Epub 2007 Jan 8. Oncogene. 2007. PMID: 17213810 - Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Travaglini L, et al. Int J Biochem Cell Biol. 2009 Jan;41(1):225-34. doi: 10.1016/j.biocel.2008.08.019. Epub 2008 Aug 22. Int J Biochem Cell Biol. 2009. PMID: 18789398 - Epigenetic information and estrogen receptor alpha expression in breast cancer.
Giacinti L, Claudio PP, Lopez M, Giordano A. Giacinti L, et al. Oncologist. 2006 Jan;11(1):1-8. doi: 10.1634/theoncologist.11-1-1. Oncologist. 2006. PMID: 16401708 Review. - Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K. Fleury L, et al. Oncogene. 2008 Jul 3;27(29):4075-85. doi: 10.1038/onc.2008.41. Epub 2008 Mar 3. Oncogene. 2008. PMID: 18317449 - Chromatin-remodelling mechanisms in cancer.
Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, Martínez-López W. Lafon-Hughes L, et al. Mutat Res. 2008 Mar-Apr;658(3):191-214. doi: 10.1016/j.mrrev.2008.01.008. Epub 2008 Feb 17. Mutat Res. 2008. PMID: 18403253 Review.
Cited by
- Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J, Gu T, Chaudhry N, Davidson NE, Huang Y. Yin J, et al. Front Immunol. 2024 Jan 10;14:1325615. doi: 10.3389/fimmu.2023.1325615. eCollection 2023. Front Immunol. 2024. PMID: 38268926 Free PMC article. Review. - Review on Natural Agents as Aromatase Inhibitors: Management of Breast Cancer.
Singh S. Singh S. Comb Chem High Throughput Screen. 2024;27(18):2623-2638. doi: 10.2174/0113862073269599231009115338. Comb Chem High Throughput Screen. 2024. PMID: 37861041 Review. - DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy.
Man X, Li Q, Wang B, Zhang H, Zhang S, Li Z. Man X, et al. Front Cell Dev Biol. 2022 May 10;10:916725. doi: 10.3389/fcell.2022.916725. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35620052 Free PMC article. Review. - Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Coyne GO', et al. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. Cancer Chemother Pharmacol. 2020. PMID: 32314030 Free PMC article. Clinical Trial. - miR-29a contributes to breast cancer cells epithelial-mesenchymal transition, migration, and invasion via down-regulating histone H4K20 trimethylation through directly targeting SUV420H2.
Wu Y, Shi W, Tang T, Wang Y, Yin X, Chen Y, Zhang Y, Xing Y, Shen Y, Xia T, Guo C, Pan Y, Jin L. Wu Y, et al. Cell Death Dis. 2019 Feb 21;10(3):176. doi: 10.1038/s41419-019-1437-0. Cell Death Dis. 2019. PMID: 30792382 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical